Literature DB >> 18201695

Human mesenchymal stem cell transformation is associated with a mesenchymal-epithelial transition.

Daniel Rubio1, Silvia Garcia, Teresa De la Cueva, Ma F Paz, Alison C Lloyd, Antonio Bernad, Javier Garcia-Castro.   

Abstract

Carcinomas are widely thought to derive from epithelial cells with malignant progression often associated with an epithelial-mesenchymal transition (EMT). We have characterized tumors generated by spontaneously transformed human mesenchymal cells (TMC) previously obtained in our laboratory. Immunohistopathological analyses identified these tumors as poorly differentiated carcinomas, suggesting that a mesenchymal-epithelial transition (MET) was involved in the generation of TMC. This was corroborated by microarray and protein expression analysis that showed that almost all mesenchymal-related genes were severely repressed in these TMC. Interestingly, TMC also expressed embryonic antigens and were able to integrate into developing blastocysts with no signs of tumor formation, suggesting a dedifferentiation process was associated with the mesenchymal stem cell (MSC) transformation. These findings support the hypothesis that some carcinomas are derived from mesenchymal rather than from epithelial precursors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18201695     DOI: 10.1016/j.yexcr.2007.11.017

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  30 in total

Review 1.  Mesenchymal stromal cells for cell therapy: besides supporting hematopoiesis.

Authors:  Lei Hao; Huiqin Sun; Jin Wang; Tao Wang; Mingke Wang; Zhongmin Zou
Journal:  Int J Hematol       Date:  2011-12-20       Impact factor: 2.490

2.  Sox11 is expressed in early progenitor human multipotent stromal cells and decreases with extensive expansion of the cells.

Authors:  Benjamin L Larson; Joni Ylostalo; Ryang H Lee; Carl Gregory; Darwin J Prockop
Journal:  Tissue Eng Part A       Date:  2010-07-13       Impact factor: 3.845

Review 3.  The role of mesenchymal stem/progenitor cells in sarcoma: update and dispute.

Authors:  Jilong Yang; Zhiwu Ren; Xiaoling Du; Mengze Hao; Wenya Zhou
Journal:  Stem Cell Investig       Date:  2014-10-27

4.  Gastritis promotes an activated bone marrow-derived mesenchymal stem cell with a phenotype reminiscent of a cancer-promoting cell.

Authors:  Jessica M Donnelly; Amy C Engevik; Melinda Engevik; Michael A Schumacher; Chang Xiao; Li Yang; Roger T Worrell; Yana Zavros
Journal:  Dig Dis Sci       Date:  2013-11-08       Impact factor: 3.199

Review 5.  The possible role of isolated lymphoid follicles in colonic mucosal repair.

Authors:  Ferenc Sipos; Györgyi Muzes; Orsolya Galamb; Sándor Spisák; Tibor Krenács; Kinga Tóth; Zsolt Tulassay; Béla Molnár
Journal:  Pathol Oncol Res       Date:  2009-06-26       Impact factor: 3.201

Review 6.  Developmental definition of MSCs: new insights into pending questions.

Authors:  Shishu Huang; Victor Leung; Songlin Peng; Laiching Li; Feng Juan Lu; Ting Wang; William Lu; Kenneth M C Cheung; Guangqian Zhou
Journal:  Cell Reprogram       Date:  2011-09-15       Impact factor: 1.987

Review 7.  Could cancer and infection be adverse effects of mesenchymal stromal cell therapy?

Authors:  Martha L Arango-Rodriguez; Fernando Ezquer; Marcelo Ezquer; Paulette Conget
Journal:  World J Stem Cells       Date:  2015-03-26       Impact factor: 5.326

Review 8.  Epithelial-to-mesenchymal and mesenchymal-to-epithelial transitions in the colon.

Authors:  Ferenc Sipos; Orsolya Galamb
Journal:  World J Gastroenterol       Date:  2012-02-21       Impact factor: 5.742

9.  Isolated lymphoid follicles in colon: switch points between inflammation and colorectal cancer?

Authors:  Ferenc Sipos; Györgyi Muzes
Journal:  World J Gastroenterol       Date:  2011-04-07       Impact factor: 5.742

10.  Expanded allogeneic adipose-derived stem cells (eASCs) for the treatment of complex perianal fistula in Crohn's disease: results from a multicenter phase I/IIa clinical trial.

Authors:  F de la Portilla; F Alba; D García-Olmo; J M Herrerías; F X González; A Galindo
Journal:  Int J Colorectal Dis       Date:  2012-09-29       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.